Radiopharmaceutical Manufacturing Patents: Mapping the Leaders and the Open Ground
Filing jumped +450% from 2021 to 2024 (2 to 11 records), the clearest sign yet that dose-dispensing and hot-cell claims are being staked out now, not settled history. Annual filings peaked at 27 in 2017, cooled, then rebuilt: 2021's count of 2 records grew to 11 by 2024, a +450% rise over that three-year span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read against the peak.
- 1JOHNS HOPKINS UNIVERSITY32
- 2GE HEALTHCARE LTD27
- 3ORANO MED26
- 4RADIOMEDIX INC23
- 5SCINOGY PRODUCTS PTY LTD23
See the full radiopharmaceutical manufacturing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on radiopharmaceutical manufacturing patents
How many patents cover radiopharmaceutical manufacturing?
This dataset identifies 165 published records in scope, covering shielded hot cells, aseptic dispensing, dose dispensing, transport shielding, quality-control release testing and related manufacturing steps between 2015 and the 2026-07-31 cut-off. The count reflects a specific search string combining radiopharmacy manufacturing terms with operational vocabulary, so it is narrower than the full radiopharmaceutical composition literature. Because publication lags filing by roughly eighteen months, the true 2025-2026 total will be higher once later filings publish.
Who are the leading patent holders in radiopharmaceutical manufacturing?
The ranked field spans 59 companies, led by a single assignee with 32 records against 23 for the fifth-placed filer, dropping to 6 by tenth place. The leaders in this space combine academic medical centres, established imaging and pharmaceutical companies, and specialist radiopharmaceutical manufacturers. Recent-year momentum data shows several of the top names posting flat or declining latest-year filing counts, which is more consistent with defending existing claims than expanding aggressively.
Is radiopharmaceutical manufacturing patent activity growing?
Yes, on the most recent complete data: filings rose from 2 records in 2021 to 11 in 2024, a +450% increase over that three-year span, after an earlier peak of 27 records in 2017. The intervening years show a slower period between that peak and the 2021 trough. Figures for 2025 and 2026 are still incomplete due to publication lag and should not be read as evidence of a slowdown.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Radiopharmaceutical Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.